A Long-Term Non-Interventional Registry to Assess Safety and Effectiveness of HUMIRA® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)

Trial Profile

A Long-Term Non-Interventional Registry to Assess Safety and Effectiveness of HUMIRA® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Nov 2017

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Crohn's disease
  • Focus Adverse reactions
  • Acronyms PYRAMID
  • Sponsors Abbott Laboratories; AbbVie
  • Most Recent Events

    • 01 Nov 2017 Results of a subgroup analysis assessing long-term safety and effectiveness of Adalimumab by Baseline Immunomodulator use, presented at the 25th United European Gastroenterology Week
    • 01 Nov 2017 Results assessing the long-term safety of Adalimumab by age subgroups (n=5025) presented at the 25th United European Gastroenterology Week
    • 01 Nov 2017 Results presented at the 25th United European Gastroenterology Week
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top